Preclinical Services for HIV Therapeutics

Award Date 10/15/2020
Last Date To Order 10/14/2027
Shared Ceiling $107M
Contract Type
Master IDIQ
Predecessor
Not listed
Successors

The Preclinical Services for HIV Therapeutics Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle, awarded by the National Institute of Allergy and Infectious Diseases (NIAID), provides comprehensive preclinical research and development services to support the advancement of therapeutic products for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and Mycobacterium tuberculosis (MTB). The contract encompasses seven distinct task areas including in vitro testing, compound synthesis, small animal model development, formulation services, pharmacology and toxicology studies, and a reagent program for infectious disease research materials. The primary objective is to support investigator-initiated research and collaborations by providing critical scientific resources and services that can help translate potential treatments from basic research to clinical testing.

Task orders under this vehicle typically range from $300,000 to $1.5 million, with performance periods spanning one to three years. Frequent prime contractors include Research Triangle Institute (RTI International), Southern Research Institute, Starks Associates Inc., the University of Texas Medical Branch, and Colorado State University. Most task orders are awarded on a cost-plus-fixed-fee basis and do not utilize specific set-aside designations, though Task Area B for compound synthesis is reserved for small businesses. Performance locations are predominantly located in research-intensive states such as North Carolina, California, Texas, and Alabama. The contract supports NIAID's broader mission of developing therapeutics, vaccines, and diagnostic tools for HIV and related infectious diseases, with a focus on preclinical stages of product development that prepare potential treatments for eventual clinical trials and regulatory review.

Generated 1/16/25, 12:26 AM